Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma

Haematologica

Volumn 92, Issue 1, 2007, Pages 141-142

  Wu, Shang Ju ^a   Chou, Wen Chien ^a   Ko, Bo Sheng ^a   Tien, Hwei Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Complications; Intravascular lymphoma; Rituximab

Indexed keywords

BETAMETHASONE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; MITOXANTRONE; PARACETAMOL; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; CASE REPORT; DISEASE SEVERITY; DYSPNEA; FEMALE; HUMAN; HUMAN TISSUE; HYPOTENSION; HYPOXIA; INTERSTITIAL PNEUMONIA; LUNG INFILTRATE; MALE; PATIENT MONITORING; RESPIRATORY DISTRESS; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; LUNG DISEASES; LYMPHOMA; MALE; MIDDLE AGED; TAIWAN; VASCULAR NEOPLASMS;

EID: 33846916924     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10561     Document Type: Article

References (10)

1. DiGiuseppe JA, Nelson WG, Seifter EJ, Boitnott JK, Mann RB. Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol 1994;12:2573-9.
2. Liszka U, Drlicek M, Hitzenberger P, Machacek E, Mayer H, Stockhammer G, et al. Intravascular lymphomatosis: a clinicopathological study of three cases. J Cancer Res Clin Oncol 1994;120:164-8.
3. Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 2004;127:173-83.
4. Murase T, Nakamura S, Kawauchi K, Matsuzaki H, Sakai C, Inaba T, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 2000;111:826-34.
5. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-24.
6. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64.
7. Shimazaki C, Inaba T, Nakagawa M. B-cell lymphoma-associated hemophagocytic syndrome. Leuk Lymphoma. 2000;38:121-30.
8. Ip M, Chan KW, Chan IK. Systemic inflammatory response syndrome in intravascular lymphomatosis. Intensive Care Med 1997;23:783-6.
9. Yalamanchili M, Prabhu S, Bradstreet P, Chouhdry I, Walsh J. Intravascular lymphomatosis presenting as systemic inflammatory response syndrome. Am J Med Sci 2002;324:339-41.
10. Bazhenova L, Higginbottom P, Mason J. Intravascular lymphoma: a role for single-agent rituximab. Leuk Lymphoma 2006;47:337-41.